Drugs / BHB810
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07529808 | Jul 2026 → Dec 2028 expected | colorectal cancer, gastric adenocarcinoma, gastroesophageal adenocarcinoma, gastroesophageal cancer +2 | BigHat Biosciences, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BHB810 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07529808 ↗ |
| Route | Intravenous | “IV infusion of BHB810” NCT07529808 ↗ |